New Generation Expands In AstraZeneca's Vacated Campus
This article was originally published in Scrip
When AstraZeneca plc decided three years ago to relocate its R&D headquarters from its Alderley Park campus in the Northwest of England to be nearer the biotech action around Cambridge, a research park built to accommodate thousands of scientists suddenly faced the prospect of becoming a ghost town. However, for Dr Neil Murray, CEO of local firm Redx Pharma, the site represents a great opportunity.
You may also be interested in...
After a tough summer, the UK firm has exited insolvency with new management and programs in cancer and fibrosis, having decided to shut down its anti-infectives business.
AbbVie’s Humira has been the world’s best-selling drug since 2012, and if it hadn’t been for COVID-19 it would most likely have been on track to retain its position for the 10th year in row.
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.